PDF Cover

Ivosidenib Market

Ivosidenib Market

The market for Ivosidenib was estimated at $331 million in 2024; it is anticipated to increase to $565 million by 2030, with projections indicating growth to around $881 million by 2035.

Report ID:DS1802281
Author:Debadatta Patel - Senior Consultant
Published Date:May 2025
Datatree
Life Science
Pharmaceutical
Ivosidenib
Share
Report Summary
Table of Contents
Methodology
Market Data

Global Ivosidenib Market Outlook

Revenue, 2024

$331M

Forecast, 2034

$805M

CAGR, 2024 - 2034

9.3%
The Ivosidenib industry revenue is expected to be around $362.0 million in 2025 and expected to showcase growth with 9.3% CAGR between 2025 and 2034. The recent rise in importance reflects the growing significance of Ivosidenib in the field of medicine. It seems that one of the reasons for this advancement is Ivosidenibs success in treating Acute Myeloid Leukemia (AML) a common of cancer. The continued relevance of Ivosidenib is strengthened by the increasing number of cancer cases an urgent problem that demands innovative and efficient treatment options such, as Ivosidenib. The continuous evolution of technology and the notable advancements in drug research and treatment methods are driving the increasing need for Ivosidenib and solidifying its ongoing significance, in the market.

Ivosidenib is a groundbreaking inhibitor that transforms the way cancer is treated by targeting the dehydrogenase enzyme (IDH) which plays a crucial role in the growth of variouss of cancer. This special feature makes Ivosidenib an essential treatment option in the field of medicine and specifically, for Acute Myeloid Leukemia (AML).

Ivosidenib market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034

Market Key Insights

  • The Ivosidenib market is projected to grow from $331.2 million in 2024 to $806 million in 2034. This represents a CAGR of 9.3%, reflecting rising demand across AML Treatment, Advanced Cholangiocarcinoma Therapy and Research & Development.
  • Agios Pharmaceuticals, Astellas Pharma, AstraZeneca are among the leading players in this market, shaping its competitive landscape.
  • U.S. and Germany are the top markets within the Ivosidenib market and are expected to observe the growth CAGR of 6.8% to 9.8% between 2024 and 2030.
  • Emerging markets including Brazil, Indonesia and South Africa are expected to observe highest growth with CAGR ranging between 8.9% to 11.6%.
  • Transition like Precision Oncologys Advancements is expected to add $66.7 million to the Ivosidenib market growth by 2030
  • The Ivosidenib market is set to add $475 million between 2024 and 2034, with manufacturer targeting Advanced Cholangiocarcinoma & Investigational Therapies Therapeutic Applications projected to gain a larger market share.
  • With Rising prevalence of acute myeloid leukemia , and Advancements in precision oncology, Ivosidenib market to expand 143% between 2024 and 2034.
ivosidenib market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032

Opportunities in the Ivosidenib

Ivosidenib shows potential in treating cancers linked to IDHI mutations beyond acute myeloid leukemia offering new avenues, for growth and expanding its reach in the market.

Growth Opportunities in North America and Europe

North America Outlook

The market for Ivosidenib in North America presents an outlook for manufacturers due to the increasing number of acute myeloid leukemia cases in the region. The high use of targeted therapies and the strong healthcare system are expected to boost the market growth. Insurance coverage and reimbursement policies add to the attractiveness of the field for industry players. However the presence of competition from established treatments such as chemotherapy and radiation poses obstacles. Market leaders like Agios Pharmaceuticals Inc. play a role, in shaping the competitive landscape. They persist in using methods, like developing pipelines and forming partnerships to stay ahead in the competition.

Europe Outlook

Europe has an incidence of AML which presents great prospects for companies producing Ivosidenib drugs. The advanced medical systems in countries such as Germany, the UK and France enhance the effectiveness of Ivosidenib. Moreover the supportive regulatory environment with approvals from the European Medical Agency plays a role in driving market growth. However intense competition among players, like Celgene Corporation and Novartis AG emphasizes the importance of taking strategic actions. In this region important factors like the cost of medication and growing knowledge, about therapies also play a significant role.

Market Dynamics and Supply Chain

01

Driver: Rising prevalence of Acute Myeloid Leukemia, and Increased Approval for Orphan Drugs

Recent research suggests that there is also an increase in the number of AML cases making it one of the key markets for Ivosidenibs use as an innovative inhibitor designed to target the mutated version of the isocitrate dehydrogenase 1 enzyme commonly present in AML patients. The rise in demand for Ivosidenibs application in treating AML signifies progress in its effectiveness and acceptance among patients in need of such treatment. This surge, in demand establishes Ivosidenib as a leading solution catering to an expanding group of patients battling AML. Ivosidenib, as an orphan drug, has also benefited from increased approvals and incentives from regulatory bodies worldwide. These efforts aim to provide treatment for rare diseases such as AML, where traditional R&D isnt as focused.
Advancing precision medicine through progress has also been advantageous for pharmaceuticals like Ivosidenib in the realm of precision oncology where treatment plans are also personalized based on genetic characteristics – sparking interest in drugs tailored to specific mutations such as Ivosidenib due to its focus on targeted enzyme mutations and its promising role, in precision oncology practices.
02

Restraint: Costliness of Treatment

Due to the manufacturing costs and extensive research and development involved in creating Ivosidenib therapy options for patients with advanced acute myeloid leukemia there may be a considerable obstacle to its widespread use in the market scenario For those suffering from this of cancer who are seeking effective treatments as a last resort solution Yet the expensive nature of this treatment could dissuade patients from opting for it which might influence the overall interest, in Ivosidenib within the market realm.
03

Opportunity: Fostering Technological Innovations and Forging Strategic Partnerships

By harnessin studies and advancements in personalized medicine fields. Ivosidenib has the potential to transform cancer treatments significantly. By improving techniques Ivosidenibs ability to target with precision could be boosted, resulting in increased effectiveness and competitive edge, in the market.
Partnering with firms or research organizations could invigorate the research and development initiatives of Ivosidenib while also boosting its competitive edge, in the market through fresh growth opportunities.
04

Challenge: Limited Awareness and Access

One of the bigger challenges faced by the Ivosidenib market is the lack of awareness and accessibility, especially in developing regions. Owing to limited health literacy, patients and even some healthcare providers may not only know about Ivosidenib or its benefits. This lack of awareness, coupled with restricted accessibility because of socio-economic or geographical reasons, acts as a significant , making it harder for this innovation to reach the patients in need.

Supply Chain Landscape

1
Raw Material Suppliers

Sigma-Aldrich

Merck KGaA

2
Intermediate Product Manufacturing

Pfizer

AstraZeneca

3
Production

Agios Pharmaceuticals Inc

AbbVie Inc

4
End-Users

Oncology Clinics

Hospitals

*The illustration highlights the key stakeholders within the supply chain ecosystem.

Applications of Ivosidenib in AML Treatment, Advanced Cholangiocarcinoma Therapy & Research & Development

AML Treatment

Ivosidenib is a leading-choice drug in the management of acute myeloid leukemia . Its innovative mechanism, as an isocitrate dehydrogenase-1 inhibitor, facilitates the management of the disease, particularly in patients who have relapsed or refractory AML with an IDH1 mutation. Key players like Agios Pharmaceuticals are at the forefront of bringing this targeted approach to AML treatment.

Advanced Cholangiocarcinoma Therapy

Another thrust region for Ivosidenib application is targeted therapy for advanced cholangiocarcinoma. This bile duct cancer often presents with mutations in the IDH1 gene, making it amenable for treatment with Ivosidenib. Consequently, the drugs adoption in this segment is rising, reinforced by leading biotechnology companies like Celgene Corporation implementing this novel approach in their cancer management strategies.

Research & Development

Apart from its clinical applications, Ivosidenib is also greatly employed within research and developmental settings. Scientists are continuously probing its potential in other IDH1-mutant cancer treatments, thereby expanding its application domain. Noteworthy biopharmaceutical companies such as Bristol-Myers Squibb are significantly investing in this research arena, indicating a new wave of therapeutic strategies led by Ivosidenib.

Recent Developments

December 2024

Ivosidenib registered a significant surge in prescriptions, facilitated by Medullary Pharmaceuticals extensive marketing outreach and strategic collaborations

September 2024

Cortex Biotech, a leading provider, launched a concentrated Ivosidenib dosage, expanding therapeutic applications

June 2024

Global health regulators approved Ivosidenib for expanded use in resistant acute myeloid leukemia treatment, marking a major milestone for manufacturer Neoleukin Therapeutics.

In the ever-evolving landscape of targeted therapy, the developments surrounding Ivosideniban orally administered enzyme inhibitorhave gained immense traction. With its prowess in treating certains of leukemia, Ivosidenib is being perceived as a game-changer in the oncology sector.

Impact of Industry Transitions on the Ivosidenib Market

As a core segment of the Pharmaceutical industry, the Ivosidenib market develops in line with broader industry shifts. Over recent years, transitions such as Precision Oncologys Advancements and Regulatory Impacts on Cancer Therapeutics have redefined priorities across the Pharmaceutical sector, influencing how the Ivosidenib market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Precision Oncologys Advancements

The field of oncology has undergone a change due to the emergence of personalized medicine and the use of target specific drugs like Ivosidenib to treat acute myeloid leukemia . By targeting faults within cancer cells and emphasizing precision medicine benefits in treating AML patients directly and effectively has revolutionized oncology towards a more tailored approach rather, than the traditional trial and error methods. The demand for Ivosidenib in the market has increased due to precision oncology. Its capacity to distinguish tumors genetically has opened up avenues, for treatment options. This industry transition is expected to add $66.7 million in the industry revenue between 2024 and 2030.
02

Regulatory Impacts on Cancer Therapeutics

Regulatory bodies worldwide have started to recognize the value of innovative therapies like Ivosidenib. In response to this need, the FDA has granted accelerated approvals for breakthrough drugs including Ivosidenib, thus fostering an expedited pathway to market for such lifesaving treatments.

Related Reports

Loading related reports...